Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.

@article{Popovi2009LisdexamfetamineAP,
  title={Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.},
  author={Biljana {\vC}. Popovi{\'c} and Pratik D. Bhattacharya and Lalitha Sivaswamy},
  journal={American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
  year={2009},
  volume={66 22},
  pages={
          2005-12
        }
}
PURPOSE The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, dosage, and administration of lisdexamfetamine are reviewed. SUMMARY Lisdexamfetamine is the first prodrug formulation of the stimulant dextroamphetamine. It is approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children age 6-12 years and adults. Due to the need for enzymatic hydrolysis, there is a decreased liability for misuse and diversion with… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Validation of the ADHD Rating Scale as a clinician administered and scored instrument

  • DE Faries, I Yalicn, D Harder
  • J Atten Disord
  • 2001
Highly Influential
7 Excerpts

Lisdexamfetamine. Paediatric Drugs

  • SK Blick, GM Keating
  • 2007
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…